

MEDICATION COVERAGE POLICY



PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE

POLICY:	Multiple Sclerosis	P&T DATE:	03/10/2026
CLASS:	Neurologic Disorders	REVIEW HISTORY:	3/25, 6/24, 1/24, 12/22, 9/21, 5/20,
LOB:	MCL/Medicare	(month/year)	2/19, 12/17, 12/16, 9/15, 5/13

This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the Health Plan of San Joaquin/Mountain Valley Health Plan (Health Plan) Pharmacy and Therapeutic Advisory Committee.

Effective 1/1/2022, the Pharmacy Benefit is regulated by Medi-Cal Rx. Please visit <https://medi-calrx.dhcs.ca.gov/home/> for portal access, formulary details, pharmacy network information, and updates to the pharmacy benefit. All medical claims require that an NDC is also submitted with the claim. If a physician administered medication has a specific assigned CPT code, that code must be billed with the correlating NDC. If there is not a specific CPT code available for a physician administered medication, the use of unclassified CPT codes is appropriate when billed with the correlating NDC.

This coverage policy is updated on an annual basis. For more recent or up-to-date criteria, reference the Medi-Cal Provider Manual and/or the Medicare National Coverage Determination/Local Coverage Determination (NCD/LCD) for specific criteria. If the Medi-Cal Provider Manual and/or the Medicare NCD/LCD do not have medical necessity criteria, please refer to the "Evaluation Criteria" section in this policy for specific criteria. It is also important to reference the Medicare Benefit Manuals - Chapter 15 and Chapter 16 - when determining benefit coverage and criteria for review of physician administered drugs on the Medicare benefit.

☒ OVERVIEW

For agents listed for coverage under the medical benefit, this coverage is specific to outpatient coverage only (excludes emergency room and inpatient coverage).

Guidelines used in the creation of this policy include the following (please review the references section for all the relevant literature used):

The American Academy of Neurology 2018 Practice guideline recommendations: Disease-modifying therapies for adults with multiple sclerosis⁹: [https://doi.org/ 10.1212/WNL.0000000000005347](https://doi.org/10.1212/WNL.0000000000005347)

Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines²⁴: <https://doi.org/10.1016/j.msard.2024.105435>

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023²⁵: [https://doi.org/ 10.1016/j.nrleng.2024.01.003](https://doi.org/10.1016/j.nrleng.2024.01.003)

☒ MEDI-CAL EVALUATION CRITERIA FOR APPROVAL/EXCEPTION CONSIDERATION

Below are the coverage criteria and required information for agents with medical benefit restrictions. This coverage criteria has been reviewed and approved by the Health Plan Pharmacy & Therapeutics (P&T) Advisory Committee. For agents that do not have established prior authorization criteria, Health Plan will make the determination based on Medical Necessity criteria as described in Health Plan Medical Review Guidelines (UM06).

Interferons

Interferon β -1b (Betaseron), Interferon β -1a (Avonex), Interferon β -1a (Rebif)

- Coverage Criteria:** Prior Authorization required unless used for Multiple Sclerosis and the provider is in network.
- Limits:** None
- Required Information for Approval:** None

Biologic

Glatiramer (Glatopa)

- Coverage Criteria:** Prior Authorization required unless used for Multiple Sclerosis and the provider is in network.
- Limits:** None
- Required Information for Approval:** None

Antineoplastic Agents

Mitoxantrone (Novantrone)

- Coverage Criteria:** Reserved as third line therapy for multiple sclerosis (MS) behind [1] Betaseron / Avonex / Rebif / Glatopa, AND [2] Gilenya, Aubagio, Tecfidera, or Vumerity due to increased risk of developing progressive multifocal leukoencephalopathy (PML). Documentation of a negative anti-JCV antibody test is required at initiation and annually for continuation.
- Limits:** None
- Required Information for Approval:** Prescription must be written by a neurologist. Patient must have chart notes showing a diagnosis of Multiple Sclerosis. Additionally, patient must have documented treatment failure of the above two categories (1st line and 2nd line MS drugs).

Alemtuzumab (Lemtrada)

- Coverage Criteria:** Reserved for patients with relapsing remitting multiple sclerosis (RRMS) with inadequate treatment response to one drug from the following two categories: [1] Betaseron / Avonex / Rebif / Glatopa, AND [2] Gilenya, Aubagio, Tecfidera, or Vumerity. Members must have no previous history of malignancy, and documentation of negative HIV, HBV, HCV, and TB tests.
- Limits:** None
- Required Information for Approval:** Prescription must be written by a neurologist. Patient must have chart notes showing a diagnosis of Multiple Sclerosis. Additionally, patient must have documented treatment failure of the above two categories (1st line and 2nd line MS drugs). Documentation that the member is negative for latent or active infections.
- Other Notes:** Daclizumab (Zinbryta) was discontinued by the manufacturer in March 2018 due to the drug's concerning benefit/risk profile.

Anti-CD20 Monoclonal Antibodies

Ocrelizumab (Ocrevus), Ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo)

- Coverage Criteria:**
 - **For patients with Relapsing MS (RMS), Ocrevus and Ocrevus Zunovo are reserved for patients who meet all of the following criteria:**
 - [A] Patient must either:
 - [1] Have had an inadequate treatment response to one drug from each of the following two categories: [i] Betaseron / Avonex / Rebif / Glatopa, AND [ii] Gilenya, Aubagio, Tecfidera, or Vumerity; OR
 - [2] Require high efficacy therapy due to meeting one of the following criteria:
 - EDSS score of ≥ 4 at 5 years of onset of the disease
 - EDSS score ≥ 6 by 40 years of age
 - Multiple relapses (two or more) in the previous year

- One relapse in the previous year with poor prognosis due to incomplete remission and/or followed by disability
- A minimum of 2 brain magnetic resonance imaging (MRI) studies with new lesions or increase in the size of the lesions in T2, or lesions that enhance with gadolinium despite adherence to MS treatment for at least 6 months
- ≥ 2 gadolinium-enhancing lesions on T1-weighted sequences or ≥ 9 lesions on T2-weighted sequences
- MRI lesions in the infratentorial region or spinal cord
- Multiple factors indicating poor prognosis (such as biomarkers, demographic factors, clinical factors, and/or radiological factors)
- [B] Prescribed by a neurologist
- [C] Lab documentation of a quantitative serum immunoglobulin test and a negative Hepatitis B Virus (HBV), at initiation
- For patients with **Primary Progressive Multiple Sclerosis (PPMS)**, members must documentation of a quantitative serum immunoglobulin test and negative HBV test at initiation. Prescription must be written by a neurologist and patient must have chart notes showing a diagnosis of PPMS.
- ☐ **Limits:** None
- ☐ **Required Information for Approval:** Prescription must be written by a neurologist. Patient must have chart notes showing a diagnosis of Multiple Sclerosis members and must have a quantitative serum immunoglobulin test and negative HBV test at initiation. Additionally, patient must have documented treatment failure of the above two categories (1st line and 2nd line MS drugs) OR meet criteria for high efficacy therapy.

Ublituximab-xiyy (Briumvi)

- ☐ **Coverage Criteria:**
 - **For patients with Relapsing MS (RMS), Briumvi is reserved for patients who meet all of the following criteria:**
 - [A] Patient must either:
 - [1] Have had an inadequate treatment response to one drug from each of the following two categories: [i] Betaseron / Avonex / Rebif / Glatopa, AND [ii] Gilenya, Aubagio, Tecfidera, or Vumerity; OR
 - [2] Require high efficacy therapy due to meeting one of the following criteria:
 - EDSS score of ≥ 4 at 5 years of onset of the disease
 - EDSS score ≥ 6 by 40 years of age
 - Multiple relapses (two or more) in the previous year
 - One relapse in the previous year with poor prognosis due to incomplete remission and/or followed by disability
 - A minimum of 2 brain magnetic resonance imaging (MRI) studies with new lesions or increase in the size of the lesions in T2, or lesions that enhance with gadolinium despite adherence to MS treatment for at least 6 months
 - ≥ 2 gadolinium-enhancing lesions on T1-weighted sequences or ≥ 9 lesions on T2-weighted sequences
 - MRI lesions in the infratentorial region or spinal cord
 - Multiple factors indicating poor prognosis (such as biomarkers, demographic factors, clinical factors, and/or radiological factors)
 - [B] Prescribed by a neurologist
 - [C] Lab documentation of a quantitative serum immunoglobulin test and a negative Hepatitis B Virus (HBV), at initiation

- Limits:** None
- Required Information for Approval:** Prescription must be written by a neurologist. Patient must have chart notes showing a diagnosis of Multiple Sclerosis members and must have a quantitative serum immunoglobulin test and a negative HBV test at initiation. Additionally, patient must have documented treatment failure of the above two categories (1st line and 2nd line MS drugs) OR meet criteria for high efficacy therapy.

Selective Adhesion-Molecule Inhibitor

Natalizumab (Tysabri), Natalizumab-sztn (Tyruko)

- Coverage Criteria:** Reserved as third line therapy for MS behind [1] Betaseron / Avonex / Rebif / Glatopa, AND [2] Gilenya, Aubagio, Tecfidera, or Vumerity due to increased risk of developing progressive multifocal leukoencephalopathy (PML). Documentation of a negative anti-JCV antibody test is required at initiation and annually for continuation.
 - Limits:** None
- Required Information for Approval:** Prescription must be written by a neurologist. Patient must have chart notes showing a diagnosis of Multiple Sclerosis. Additionally, patient must have documented treatment failure of the above two categories (1st line and 2nd line MS drugs).

REFERENCES

1. Ocrevus (ocrelizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; March 2017.
2. Hauser, SL, Bar-Or, A, Comi, G; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *N Engl J Med.* 2017;376(3):221-234.
3. Montalban, X, Hauser, SL, Kappos, L; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. *N Engl J Med.* 2017;376(3):209-220.
4. National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. <http://nice.org.uk/guidance/cg186>. Published October 8, 2014
5. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology [Internet].* 2008 Sep 2;71(10):766-73
6. Laplaud D, Bodiguel E, Bensa C, Blanc F, Brassat D, Magy L, et al. Recommendations for the management of multiple sclerosis relapses. *Rev Neurol (Paris).* 2012 May;168(5):425-33.
7. Cortese, I. et al. "Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology." *Neurology* 76.3 (2011): 294–300. PMC. Web. 21 Nov. 2017.
8. Selmaj K, Barkhof F, Belova AN et al (2017) Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. *Mult Scler.* doi:10.1177/1352458516688956
9. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 2018;90:777–788.
10. Han DH. Bafiertam gets tentative approval for relapsing multiple sclerosis. <https://www.empr.com/news/multiple-sclerosis-treatment-bafiertam-monomethyl-fumarate-tentative-approval/article/824287/>. Updated January 2, 2019. Accessed January 28, 2019.
11. Specialty Drug Approvals: 2018 Highlights and 2019 Projections. *Diplomat.* 2018.
12. Q1PipelineReport-Booklet. *Diplomat.* 2019.
13. Keown A. Celgene Plans to File Second NDA for Ozanimod in 2019 Following FDA Rejection in February. <https://www.biospace.com/article/celgene-plans-to-file-second-nda-for-ozanimod-in-2019-following-fda-rejection-in-february/>. Updated May 4, 2018. Accessed January 28, 2019.
14. Vumerity (diroximel fumarate) [prescribing information]. Waltham, MA: Alkermes, Inc. October 2019.
15. LaMotta L. Gilenya patent decision gives MS market a reprieve. *BioPharma Dive Website.* <https://www.biopharmadive.com/news/gilenya-patent-decision-gives-ms-market-a-reprieve/527758/>. Updated July 13, 2018. Accessed January 28, 2019.
16. Kesimpta (ofatumumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. August 2020.
17. Ponvory (ponesimod) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2021.
18. Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis for the ASCLEPIOS I and ASCLEPIOS II Trial Groups. *N Engl J Med.* 2020; 383:546-557.
19. Kappos L, Fox RJ, Burcklen M, et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. *JAMA Neurol.* 2021;78(5):558–567. doi:10.1001/jamaneurol.2021.0405
20. Center for Drug Evaluation and Research. Novel drug approvals at FDA. U.S. Food and Drug Administration. Accessed February 19, 2025. <https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda>.
21. TG Therapeutics. Briumvi (Ublituximab-xiyy) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761238s011bl.pdf. Revised October 2024. Accessed February 19, 2025.
22. Sandoz Inc. Tyruko (natalizumab-sztn) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761322s000lblcorrection.pdf. Revised August 2023. Accessed February 19, 2025.
23. Genentech. Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761371s000lbl.pdf. Revised September 2024. Accessed February 19, 2025.
24. Yamout B, Al-Jumah M, Sahraian MA, Almalik Y, Khaburi JA, Shalaby N, Aljarallah S, Bohlega S, Dahdaleh M, Almahdawi A, Khoury SJ, Koussa S, Slassi E, Daoudi S, Aref H, Mrabet S, Zeineddine M, Zakaria M, Inshasi J, Gouider R, Alroughani R. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS

guidelines. *Mult Scler Relat Disord*. 2024 Mar;83:105435. doi: 10.1016/j.msard.2024.105435. Epub 2024 Jan 7. PMID: 38245998.

25. Meca-Lallana JE, Martínez Yélamos S, Eichau S, Llaneza MÁ, Martín Martínez J, Peña Martínez J, Meca Lallana V, Alonso Torres AM, Moral Torres E, Río J, Calles C, Ares Luque A, Ramió-Torrentà L, Marzo Sola ME, Prieto JM, Martínez Ginés ML, Arroyo R, Otano Martínez MÁ, Brieva Ruiz L, Gómez Gutiérrez M, Rodríguez-Antigüedad Zarranz A, Sánchez-Seco VG, Costa-Frossard L, Hernández Pérez MÁ, Landete Pascual L, González Platas M, Oreja-Guevara C. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023. *Neurologia (Engl Ed)*. 2024 Mar;39(2):196-208. doi: 10.1016/j.nrleng.2024.01.003. Epub 2024 Jan 16. PMID: 38237804.
26. Díaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: An update. *Mult Scler Relat Disord*. 2019 May;30:215-224. doi: 10.1016/j.msard.2019.01.039. Epub 2019 Jan 24. PMID: 30822617.

REVIEW & EDIT HISTORY

Document Changes	Reference	Date	P&T Chairman
Creation of Policy	MS Drug Class Review 5-21-2013.docx	5/2013	Jonathan Szkotak, PharmD BCACP
Updated Policy	Tecfidera Monograph 2014-09-16.docx	9/2014	Jonathan Szkotak, PharmD BCACP
Updated Policy	HPSJ Coverage Policy - Neurologic Disorders - Multiple Sclerosis 2015-09.docx	9/2015	Jonathan Szkotak, PharmD BCACP
Updated Policy	HPSJ Coverage Policy - Neurologic Disorders - Multiple Sclerosis 2016-12.docx	12/2016	Johnathan Yeh, PharmD
Updated Policy	HPSJ Coverage Policy - Neurologic Disorders - Multiple Sclerosis 2017-12.docx	12/2017	Johnathan Yeh, PharmD
Updated Policy	HPSJ Coverage Policy - Neurologic Disorders - Multiple Sclerosis 2019-02.docx	2/2019	Matthew Garrett, PharmD
Updated Policy	Multiple Sclerosis.docx	5/2020	Matthew Garrett, PharmD
Updated Policy	Multiple Sclerosis.docx	9/2021	Matthew Garrett, PharmD
Review of Policy	Multiple Sclerosis	12/2022	Matthew Garrett, PharmD
Review of Policy	Multiple Sclerosis	1/2024	Matthew Garrett, PharmD
Review of Policy	Multiple Sclerosis	6/2024	Matthew Garrett, PharmD
Review of Policy	Multiple Sclerosis	3/2025	Matthew Garrett, PharmD
Review of Policy	Multiple Sclerosis	3/2026	Matthew Garrett, PharmD

Note: All changes are approved by the Health Plan P&T Committee before incorporation into the utilization policy